Publications by authors named "Julia Garcia Consuegra"
Unlabelled: Intra-articular corticosteroid injections (IACI) are one of the mainstays of treatment for children with juvenile idiopathic arthritis. The most important disadvantage of IACI is the pain associated with the procedure. Little is known about the children or parents' perception of this pain.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to assess the effectiveness of the Birmingham Vasculitis Activity Score (BVAS) v3 and the Disease Extent Index (DEI) in measuring disease activity in four main types of childhood systemic vasculitides.
- A total of 796 patients with conditions like Henoch-Schönlein purpura and polyarteritis nodosa were analyzed, revealing a strong correlation between BVAS and DEI scores, as well as their ability to reflect disease involvement.
- The findings confirm that both BVAS and DEI are reliable tools for evaluating disease activity in children with these vasculitides.
Context: Novel therapies have improved the remission rate in chronic inflammatory disorders including juvenile idiopathic arthritis (JIA). Therefore, strategies of tapering therapy and reliable parameters for detecting subclinical inflammation have now become challenging questions.
Objectives: To analyze whether longer methotrexate treatment during remission of JIA prevents flares after withdrawal of medication and whether specific biomarkers identify patients at risk for flares.
Article Synopsis
- The study investigates the phenotype characteristics of pediatric granulomatous arthritis (PGA) patients with NOD2 gene mutations, using data from two cohorts: the International PGA Registry and a Spanish cohort.
- Forty-five patients were analyzed, revealing a range of mutations with the most common being R334W and R334Q, alongside typical symptoms like dermatitis, uveitis, and arthritis, as well as various atypical manifestations in some cases.
- The findings emphasize that NOD2-associated PGA can affect multiple systems in the body, suggesting that healthcare providers need to be aware of its potential systemic complications to prevent long-term health issues.
NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort.
Arthritis Rheum
November 2007
Article Synopsis
- The study focuses on Blau syndrome and early-onset sarcoidosis, both linked to the NOD2 gene, exploring their clinical features, treatment outcomes, and genetic mutations in a Spanish pediatric cohort.
- Among 12 patients, only 41.7% exhibited the classic triad of symptoms, while 58.3% had incomplete manifestations, along with some atypical features like fever and myocardiopathy.
- NOD2 gene analysis revealed various mutations, predominantly affecting families, and showed that treatment with anakinra led to significant clinical improvement in one patient, highlighting the potential genetic basis of these chronic conditions.
Objective: To report the case of a child diagnosed with polyarteritis nodosa (PAN) that was unresponsive to conventional treatment alone but improved with the addition of iloprost and bosentan to her drug regimen.
Case Summary: A 3-year-old girl who had been diagnosed with PAN was referred to our hospital from another region. With conventional treatment of high doses of a corticosteroid and cyclophosphamide, her condition resolved.
Objective: To evaluate the revised (Edmonton 2001) International League of Associations for Rheumatology (ILAR) classification criteria for Juvenile Idiopathic Arthritis (JIA) in a cohort of Spanish children.
Methods: One hundred twenty-five patients with chronic arthritis categorized according to traditional criteria and to the first revision of ILAR JIA criteria (Durban 1997) were reclassified according to the second JIA criteria revision (Edmonton 2001).
Results: Edmonton criteria allocated 92% of the patients classified by traditional criteria in their corresponding ILAR categories.
Objective: To characterize pediatric patients who had been diagnosed with polyarteritis nodosa (PAN) through necrotizing vasculitis of the small and mid-size arteries or those with characteristic findings on angiograms data were collected.
Study Design: Pediatricians were asked to classify their patients into one of the four suggested groups for juvenile PAN. Twenty-one pediatric centers worldwide participated with 110 patients.
A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate.
Arthritis Rheum
July 2004
Objective: To compare the safety and efficacy of parenteral methotrexate (MTX) at an intermediate dosage (15 mg/m(2)/week) versus a higher dosage (30 mg/m(2)/week) in patients with polyarticular-course juvenile idiopathic arthritis (JIA) who failed to improve while receiving standard dosages of MTX (8-12.5 mg/m(2)/week).
Methods: In the screening phase, 595 patients who were newly started on a standard dose of MTX were followed up for 6 months.